Dose-Specific Effects of Denosumab on Serum Calcium Levels in Patients With Osteoporosis and Various Renal Functions
Authors' conclusion
The magnitude of serum calcium decrease following subsequent dose(s) was smaller than that following the initial dose of denosumab among patients with osteoporosis and advanced CKD.
Study context
- Population
- Patients with osteoporosis and varying renal function receiving denosumab, Mass General Brigham healthcare system, 2016–2024159 with data for 3 doses
- Participants
- 10,398 patients
- Exposure
- Initial vs subsequent denosumab doses, by glomerular filtration rate (GFR) category
- GFR ≥60n = 89
- GFR 30 to 59n = 46
- GFR <30n = 24
- Outcome
- Dose-specific effects of denosumab on serum calcium and incidence of hypocalcemia (albumin-corrected serum calcium < 8.5 mg/dL)
Methodological detailsconsecutive patients, single healthcare system
- Consecutive patients
- Single healthcare system
Main finding
As reported in the abstract
Reduction in serum calcium after initial denosumab dose
GFR ≥60
0.34
mean · mg/dL
GFR 30 to 59
0.52
mean · mg/dL
GFR <30
1.12
mean · mg/dL
P < 0.001
Observational data: associations, not effects.
Further findings
- Kaplan-Meier: trend of higher hypocalcemia incidence after initial than second dose in GFR < 30
- Cohort of 325 with data for 2 doses
Original publication
Dose-Specific Effects of Denosumab on Serum Calcium Levels in Patients With Osteoporosis and Various Renal Functions. J Clin Endocrinol Metab. Published 11 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →